FR2837835B1 - Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant - Google Patents

Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant

Info

Publication number
FR2837835B1
FR2837835B1 FR0204037A FR0204037A FR2837835B1 FR 2837835 B1 FR2837835 B1 FR 2837835B1 FR 0204037 A FR0204037 A FR 0204037A FR 0204037 A FR0204037 A FR 0204037A FR 2837835 B1 FR2837835 B1 FR 2837835B1
Authority
FR
France
Prior art keywords
strain
immune system
same
bacillus subtilis
recombinant vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0204037A
Other languages
English (en)
Other versions
FR2837835A1 (fr
Inventor
Maria Urdaci
Irina Pinchuk
Francis Megraud
Iryna Sorokulova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0204037A priority Critical patent/FR2837835B1/fr
Publication of FR2837835A1 publication Critical patent/FR2837835A1/fr
Application granted granted Critical
Publication of FR2837835B1 publication Critical patent/FR2837835B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0204037A 2002-03-29 2002-03-29 Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant Expired - Fee Related FR2837835B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0204037A FR2837835B1 (fr) 2002-03-29 2002-03-29 Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204037A FR2837835B1 (fr) 2002-03-29 2002-03-29 Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant

Publications (2)

Publication Number Publication Date
FR2837835A1 FR2837835A1 (fr) 2003-10-03
FR2837835B1 true FR2837835B1 (fr) 2007-06-22

Family

ID=27839360

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0204037A Expired - Fee Related FR2837835B1 (fr) 2002-03-29 2002-03-29 Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant

Country Status (1)

Country Link
FR (1) FR2837835B1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358164A (zh) * 2013-06-28 2016-02-24 乐斯福公司 治疗和/或预防慢性炎症疾病的菌株

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
FR3007654B1 (fr) * 2013-06-27 2015-07-10 Lesaffre & Cie Composition de solute de rehydratation orale contenant des probiotiques
CN114686396A (zh) * 2021-12-23 2022-07-01 微康益生菌(苏州)股份有限公司 一种抗幽门螺杆菌的凝结芽孢杆菌bc99及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
WO1999021959A2 (fr) * 1997-10-28 1999-05-06 Genome Therapeutics Corporation FORMULATIONS VACCINALES A BASE DE $i(HELICOBACTER PYLORI)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358164A (zh) * 2013-06-28 2016-02-24 乐斯福公司 治疗和/或预防慢性炎症疾病的菌株
CN105358164B (zh) * 2013-06-28 2020-01-03 乐斯福公司 治疗和/或预防慢性炎症疾病的菌株

Also Published As

Publication number Publication date
FR2837835A1 (fr) 2003-10-03

Similar Documents

Publication Publication Date Title
EP1567639A4 (fr) Culture d'ilots pancreatiques humains et leurs utilisations
WO2003101397A3 (fr) Vaccins tetravalents contre la dengue
AU2003221704A8 (en) Immunogenic peptides, and method of identifying same
WO2004069156A3 (fr) Bacteries probiotiques inactivees et leurs procedes d'utilisation
DE60328481D1 (de) Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
AU2003235707A8 (en) Immunogenic preparations and vaccines on the basis of mrna
EP1551376A4 (fr) Compositions immunomodulatrices, leurs methodes de preparation et utilisation
EP1594536A4 (fr) Vaccin contre la grippe contenant un adjuvant
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
EP1545599A4 (fr) Compositions immunogenes et utilisations diagnostiques et therapeutiques de celles-ci
HK1088225A1 (en) Compositions comprising immunomodulatory compoundsfor treatment, modification and management of pai n
EP1569514A4 (fr) Antigene specifique de tumeurs, peptides associes et utilisation de ceux-ci en tant que vaccins antitomoraux
AU2003297199A8 (en) Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
DE60312211D1 (de) Haarbehandlungsmittel
EP1515768A4 (fr) Methodes, dispositifs et formulations pour therapie endobronchique ciblee
ITMI20030511A1 (it) Dispositivo per la cura dei capelli dotato di casco.
FR2837835B1 (fr) Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant
AU2003300435A8 (en) Tissue and organ preservation, protection and resuscitation
PL373148A1 (en) Spherical pellet formulations
AU2002246983A1 (en) 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha
AP2003002914A0 (en) Novel expression vectors and uses thereof.
DE60226057D1 (de) Geflügelkrankheit verursachendes bakterium und daraus stammender impfstoff
AU2003289155A1 (en) Thermoelectric effect apparatus, energy direct conversion system, and energy conversion system
WO2006095176A3 (fr) Formulation de vaccin
PL374858A1 (en) Novel arylimidazole derivatives, preparation and therapeutic uses thereof

Legal Events

Date Code Title Description
CL Concession to grant licences

Name of requester: SAFISIS, FR

Effective date: 20130205

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20201109